Global Lipid Nanoparticle (LNP) Formulation Service Market Research Report 2025

Publication ID:

PB503250257

Publication Date:

March 11, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Lipid Nanoparticle (LNP) Formulation Service was valued at US$ 6400 million in the year 2024 and is projected to reach a revised size of US$ 13760 million by 2031, growing at a CAGR of 11.5% during the forecast period.
LNPs (Lipid Nanoparticles) are a novel potential delivery tool in the 100-150 nanometer range, serving as an important alternative to polymer systems. LNPs are lipophilic substances that have been shown to effectively deliver nucleic acid-based therapeutic products. This delivery system utilizes biocompatible lipid materials as carriers, capable of dissolving, encapsulating, adsorbing, and attaching drugs or other bioactive substances. Compared to other delivery systems, LNPs offer numerous advantages, including enhanced drug absorption, modified drug toxicity, improved drug stability, and controlled drug release. As a result, LNPs play an increasingly important role in the delivery of gene therapies, anticancer drugs, proteins, and peptides.
North American market for Lipid Nanoparticle (LNP) Formulation Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Lipid Nanoparticle (LNP) Formulation Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Lipid Nanoparticle (LNP) Formulation Service in Gene Therapy is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Lipid Nanoparticle (LNP) Formulation Service include GenScript, Creative Biolabs, Merck, Cytiva, WuXi STA, Carcell, Croda International, Detai Biotechnology, Waters, MicroNano Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Lipid Nanoparticle (LNP) Formulation Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lipid Nanoparticle (LNP) Formulation Service.
The Lipid Nanoparticle (LNP) Formulation Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lipid Nanoparticle (LNP) Formulation Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lipid Nanoparticle (LNP) Formulation Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GenScript
Creative Biolabs
Merck
Cytiva
WuXi STA
Carcell
Croda International
Detai Biotechnology
Waters
MicroNano Biologics
Precigenome
Evonik
Avanti Polar Lipids
Genevant Sciences
Nippon Fine Chemical
Lipoid
Segment by Type
Solid Lipid Nanoparticles
Nanostructured Lipid Carriers
Cationic Lipid-Nucleic Acid Complexes
Segment by Application
Gene Therapy
Vaccine Development
Cancer Treatment
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lipid Nanoparticle (LNP) Formulation Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lipid Nanoparticle (LNP) Formulation Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Solid Lipid Nanoparticles
1.2.3 Nanostructured Lipid Carriers
1.2.4 Cationic Lipid-Nucleic Acid Complexes
1.3 Market by Application
1.3.1 Global Lipid Nanoparticle (LNP) Formulation Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Gene Therapy
1.3.3 Vaccine Development
1.3.4 Cancer Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lipid Nanoparticle (LNP) Formulation Service Market Perspective (2020-2031)
2.2 Global Lipid Nanoparticle (LNP) Formulation Service Growth Trends by Region
2.2.1 Global Lipid Nanoparticle (LNP) Formulation Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lipid Nanoparticle (LNP) Formulation Service Historic Market Size by Region (2020-2025)
2.2.3 Lipid Nanoparticle (LNP) Formulation Service Forecasted Market Size by Region (2026-2031)
2.3 Lipid Nanoparticle (LNP) Formulation Service Market Dynamics
2.3.1 Lipid Nanoparticle (LNP) Formulation Service Industry Trends
2.3.2 Lipid Nanoparticle (LNP) Formulation Service Market Drivers
2.3.3 Lipid Nanoparticle (LNP) Formulation Service Market Challenges
2.3.4 Lipid Nanoparticle (LNP) Formulation Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lipid Nanoparticle (LNP) Formulation Service Players by Revenue
3.1.1 Global Top Lipid Nanoparticle (LNP) Formulation Service Players by Revenue (2020-2025)
3.1.2 Global Lipid Nanoparticle (LNP) Formulation Service Revenue Market Share by Players (2020-2025)
3.2 Global Top Lipid Nanoparticle (LNP) Formulation Service Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lipid Nanoparticle (LNP) Formulation Service Revenue
3.4 Global Lipid Nanoparticle (LNP) Formulation Service Market Concentration Ratio
3.4.1 Global Lipid Nanoparticle (LNP) Formulation Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lipid Nanoparticle (LNP) Formulation Service Revenue in 2024
3.5 Global Key Players of Lipid Nanoparticle (LNP) Formulation Service Head office and Area Served
3.6 Global Key Players of Lipid Nanoparticle (LNP) Formulation Service, Product and Application
3.7 Global Key Players of Lipid Nanoparticle (LNP) Formulation Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lipid Nanoparticle (LNP) Formulation Service Breakdown Data by Type
4.1 Global Lipid Nanoparticle (LNP) Formulation Service Historic Market Size by Type (2020-2025)
4.2 Global Lipid Nanoparticle (LNP) Formulation Service Forecasted Market Size by Type (2026-2031)
5 Lipid Nanoparticle (LNP) Formulation Service Breakdown Data by Application
5.1 Global Lipid Nanoparticle (LNP) Formulation Service Historic Market Size by Application (2020-2025)
5.2 Global Lipid Nanoparticle (LNP) Formulation Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lipid Nanoparticle (LNP) Formulation Service Market Size (2020-2031)
6.2 North America Lipid Nanoparticle (LNP) Formulation Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2020-2025)
6.4 North America Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lipid Nanoparticle (LNP) Formulation Service Market Size (2020-2031)
7.2 Europe Lipid Nanoparticle (LNP) Formulation Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2020-2025)
7.4 Europe Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Service Market Size (2020-2031)
8.2 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lipid Nanoparticle (LNP) Formulation Service Market Size (2020-2031)
9.2 Latin America Lipid Nanoparticle (LNP) Formulation Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2020-2025)
9.4 Latin America Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Service Market Size (2020-2031)
10.2 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GenScript
11.1.1 GenScript Company Details
11.1.2 GenScript Business Overview
11.1.3 GenScript Lipid Nanoparticle (LNP) Formulation Service Introduction
11.1.4 GenScript Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.1.5 GenScript Recent Development
11.2 Creative Biolabs
11.2.1 Creative Biolabs Company Details
11.2.2 Creative Biolabs Business Overview
11.2.3 Creative Biolabs Lipid Nanoparticle (LNP) Formulation Service Introduction
11.2.4 Creative Biolabs Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.2.5 Creative Biolabs Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Lipid Nanoparticle (LNP) Formulation Service Introduction
11.3.4 Merck Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.3.5 Merck Recent Development
11.4 Cytiva
11.4.1 Cytiva Company Details
11.4.2 Cytiva Business Overview
11.4.3 Cytiva Lipid Nanoparticle (LNP) Formulation Service Introduction
11.4.4 Cytiva Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.4.5 Cytiva Recent Development
11.5 WuXi STA
11.5.1 WuXi STA Company Details
11.5.2 WuXi STA Business Overview
11.5.3 WuXi STA Lipid Nanoparticle (LNP) Formulation Service Introduction
11.5.4 WuXi STA Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.5.5 WuXi STA Recent Development
11.6 Carcell
11.6.1 Carcell Company Details
11.6.2 Carcell Business Overview
11.6.3 Carcell Lipid Nanoparticle (LNP) Formulation Service Introduction
11.6.4 Carcell Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.6.5 Carcell Recent Development
11.7 Croda International
11.7.1 Croda International Company Details
11.7.2 Croda International Business Overview
11.7.3 Croda International Lipid Nanoparticle (LNP) Formulation Service Introduction
11.7.4 Croda International Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.7.5 Croda International Recent Development
11.8 Detai Biotechnology
11.8.1 Detai Biotechnology Company Details
11.8.2 Detai Biotechnology Business Overview
11.8.3 Detai Biotechnology Lipid Nanoparticle (LNP) Formulation Service Introduction
11.8.4 Detai Biotechnology Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.8.5 Detai Biotechnology Recent Development
11.9 Waters
11.9.1 Waters Company Details
11.9.2 Waters Business Overview
11.9.3 Waters Lipid Nanoparticle (LNP) Formulation Service Introduction
11.9.4 Waters Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.9.5 Waters Recent Development
11.10 MicroNano Biologics
11.10.1 MicroNano Biologics Company Details
11.10.2 MicroNano Biologics Business Overview
11.10.3 MicroNano Biologics Lipid Nanoparticle (LNP) Formulation Service Introduction
11.10.4 MicroNano Biologics Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.10.5 MicroNano Biologics Recent Development
11.11 Precigenome
11.11.1 Precigenome Company Details
11.11.2 Precigenome Business Overview
11.11.3 Precigenome Lipid Nanoparticle (LNP) Formulation Service Introduction
11.11.4 Precigenome Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.11.5 Precigenome Recent Development
11.12 Evonik
11.12.1 Evonik Company Details
11.12.2 Evonik Business Overview
11.12.3 Evonik Lipid Nanoparticle (LNP) Formulation Service Introduction
11.12.4 Evonik Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.12.5 Evonik Recent Development
11.13 Avanti Polar Lipids
11.13.1 Avanti Polar Lipids Company Details
11.13.2 Avanti Polar Lipids Business Overview
11.13.3 Avanti Polar Lipids Lipid Nanoparticle (LNP) Formulation Service Introduction
11.13.4 Avanti Polar Lipids Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.13.5 Avanti Polar Lipids Recent Development
11.14 Genevant Sciences
11.14.1 Genevant Sciences Company Details
11.14.2 Genevant Sciences Business Overview
11.14.3 Genevant Sciences Lipid Nanoparticle (LNP) Formulation Service Introduction
11.14.4 Genevant Sciences Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.14.5 Genevant Sciences Recent Development
11.15 Nippon Fine Chemical
11.15.1 Nippon Fine Chemical Company Details
11.15.2 Nippon Fine Chemical Business Overview
11.15.3 Nippon Fine Chemical Lipid Nanoparticle (LNP) Formulation Service Introduction
11.15.4 Nippon Fine Chemical Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.15.5 Nippon Fine Chemical Recent Development
11.16 Lipoid
11.16.1 Lipoid Company Details
11.16.2 Lipoid Business Overview
11.16.3 Lipoid Lipid Nanoparticle (LNP) Formulation Service Introduction
11.16.4 Lipoid Revenue in Lipid Nanoparticle (LNP) Formulation Service Business (2020-2025)
11.16.5 Lipoid Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

GenScript
Creative Biolabs
Merck
Cytiva
WuXi STA
Carcell
Croda International
Detai Biotechnology
Waters
MicroNano Biologics
Precigenome
Evonik
Avanti Polar Lipids
Genevant Sciences
Nippon Fine Chemical
Lipoid

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂